文献速递其他结缔组织病系统性红斑狼疮

抗NOR90抗体在系统性硬化症和特发性间质性肺炎中的临床意义

Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

本研究建立ELISA检测抗NOR90抗体,纳入1252例多种疾病患者和244例特发性间质性肺炎(IIP)患者。抗NOR90抗体在系统性硬化症谱系疾病中更常见,阳性SSc患者多伴间质性肺病(ILD),阳性IIP患者均有胃肠道受累,提示该抗体可能与ILD和癌症相关。

要点

  • 抗NOR90抗体在系统性硬化症谱系疾病中阳性率高于无SSD者(5/316 vs 0/936,P<0.00101)。
  • 4例抗NOR90阳性SSc患者中3例有ILD,2例有癌症。
  • 3例抗NOR90阳性IIP患者均有胃肠道受累,其中2例有癌症或SSc皮肤病变。

核心结论

  • 抗NOR90抗体在临床罕见,但本研究建立的ELISA可用于其检测。
  • 抗NOR90抗体与SSc谱系疾病相关,并可能与SSc和IIP患者的ILD及癌症相关,需进一步研究确认。

研究设计与样本

  • 研究纳入名古屋大学医院1252例多种疾病患者及东成综合医院244例特发性间质性肺炎(IIP)患者。
  • 采用体外转录/翻译重组蛋白建立ELISA检测抗NOR90抗体。

主要发现

  • 名古屋大学医院队列中5例(0.4%)抗NOR90抗体阳性,包括1例弥漫性皮肤型SSc、3例局限性皮肤型SSc和1例雷诺病。
  • 抗NOR90抗体在系统性硬化症谱系疾病(SSD)患者中阳性率高于无SSD者(5/316 vs 0/936,P<0.00101),在SSc患者中高于无SSc者(4/249 vs 0/528,P<0.0104)。
  • 4例抗NOR90阳性SSc患者中3例有间质性肺病(ILD),2例有癌症。
  • 东成综合医院队列中3例(1.2%)抗NOR90抗体阳性,均有胃肠道受累,其中2例有癌症或SSc皮肤病变。

临床怎么用

  • 对SSc谱系疾病及特发性间质性肺炎患者,可考虑检测抗NOR90抗体以辅助评估ILD和肿瘤风险。
  • 抗NOR90抗体阳性者应关注间质性肺病、胃肠道受累及恶性肿瘤筛查。

局限性

  • 抗NOR90抗体阳性例数少,关联性需更大样本研究确认。
  • 原文未报告ELISA的具体阈值、灵敏度或特异度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anti-NOR90 antibodies are usually found in patients with SSc; however, their clinical relevance remains obscure. We developed an ELISA for measuring them to investigate the clinical features of patients with anti-NOR90 antibodies. METHODS: Serum samples from 1252 patients with various conditions from Nagoya University Hospital and 244 patients with idiopathic interstitial pneumonia (IIP) from Tosei General Hospital were included. Anti-NOR90 antibodies were assayed by an ELISA using the recombinant protein produced by in vitro transcription/translation. RESULTS: Five (0.4%) patients in the Nagoya University Hospital cohort had anti-NOR90 antibodies. One patient with diffuse cutaneous SSc, three with limited cutaneous SSc, and one with Raynaud's disease were positive for anti-NOR90 antibodies. Anti-NOR90 antibodies were found more frequently in patients with systemic scleroderma-spectrum disorders (SSDs) than without SSDs (5/316 vs 0/936, P <0.00101) and were found more frequently in patients with SSc than without SSc (4/249 vs 0/528, P <0.0104) in the systemic autoimmune rheumatic diseases cohort. Three of the four anti-NOR90-positive SSc patients had interstitial lung disease (ILD), and two of those four had cancer. Three (1.2%) patients in the Tosei General Hospital cohort had anti-NOR90 antibodies. All three of the anti-NOR90-positive IIP patients had gastrointestinal tract involvement, and two of those three had cancer or skin lesions observed in SSc. CONCLUSIONS: Although anti-NOR90 antibodies are rarely found in clinics, our ELISA is useful for their detection. Further studies are needed to confirm the association of anti-NOR90 antibodies with ILD and cancer in SSc and IIP patients.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yamashita Y, Yamano Y, Muro Y, et al. Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia. Rheumatology (Oxford). 2022. PMID: 34282441. doi:10.1093/rheumatology/keab575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。